Opthea Exploring Different Approach To Treating Wet AMD

Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward.

Episode metadata supplied by the publisher feed · Published Aug 31, 2015

Embed this episode

Attribution link and audio player

NOW PLAYING

Opthea Exploring Different Approach To Treating Wet AMD

0:00 20:23

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Faut qu'on en parle !?

This episode is 20 minutes long.

When was this Faut qu'on en parle ! episode published?

This episode was published on August 31, 2015.

Can I download this Faut qu'on en parle ! episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!